BDKRB1 and arthritic joint disease: Cd13–/– mice treated with a B1R antagonist had less arthritis compared with vehicle-treated mice, but a significant decrease in arthritis severity in Cd13–/– mice was not observed until day 8, whereas WT mice treated with a B1R antagonist developed significantly less arthritis starting on day 6 (Figure 5D).